Dr Borad on the Initial Efficacy of RLY-4008 in FGFR2 Fusion–Positive Cholangiocarcinoma

Mitesh Borad, MD, key findings from the phase 1/2 ReFocus trial in FGFR2-altered cholangiocarcinoma.

Related Keywords

,Mayo Clinic Comprehensive Cancer Center ,Department Of Medical Oncology ,Medical Oncology ,Onclive Tv ,Mayo Clinic ,Rly 4008 ,Fgfr2 Fusion ,Cholangiocarcinoma ,